Minimally invasive micro sclerostomy (MIMS) procedure in the treatment of open-angle glaucoma

Lilit Voskanyan, Iqbal Ike K. Ahmed, Assaf Gershoni, Edward Barayev, Vahan Papoyan, Astghik Ghazaryan, Oren Bar-Ilan, Alon Zahavi, Yoseph Glovinsky, Noa Geffen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: To evaluate the safety and efficacy of the Minimally Invasive Micro Sclerotomy (MIMS) procedure in the management of uncontrolled open-angle glaucoma. Methods: A prospective, open-label, single-arm clinical evaluation with intra-subject comparisons performed at the Ophthalmologic Center after S.V. Malayan, Yerevan, Armenia. Included were adults with primary open-angle glaucoma (OAG) (N = 114) or exfoliative glaucoma (N = 6) who were uncontrolled (IOP > 21) on tolerated topical medication. Mild (N = 7), moderate (N = 66) and severe (n = 47) cases were prospectively included without preselection. Following subconjunctival Mitomycin C, an ab-interno MIMS procedure was performed alone (N = 100) or combined with phacoemulsification (N = 20). Patients were followed for 52 weeks. Procedure-related complications and adverse events were recorded. Success criteria were defined as -5 < IOP ≤ 21mmHg OR a reduction in IOP of ≥ 20% from baseline with (qualified success) or without (complete success) hypotensive medications. Results: Mean patient age was 69 ± 10.1 years. The mean duration of the procedure was 2:01 ± 0:41 min:sec. Scleral drainage channels were achieved in all cases. No device malfunctions, intraoperative complications, or serious adverse events were reported. Iris plugging of the sclerostomy site and early spikes in IOP were the most common adverse events. The only reason for failure was final IOP > 21 mmHg on tolerated medication. At 52 weeks (n = 93), mean IOP decreased by 38% from baseline (P < 0.001), from 27.9 ± 3.7 to 17.5 ± 5.3 mmHg, a difference of 10.5 mmHg (95% CI: -11.7, -9.3). One-year qualified success was documented in 82.1% (95% CI: 72.9%,89.2%) of the patients and complete success, in 70.5% (60.3-79.4%). 60% (95 CI:49.4%,69.9%) of the patients achieved maximum IOP level of 14 mmHg or at least 30% reduction in IOP. Conclusions: MIMS procedure is a relatively simple, short and safe minimally invasive bleb-forming procedure. Its efficacy, as found in this short-term evaluation, lends it suitable for mild and moderate uncontrolled open-angle glaucoma patients. Trial registration: ID: NCT04503590 2019-05-29.

Original languageEnglish
Article number122
JournalBMC Ophthalmology
Issue number1
StatePublished - Dec 2024


FundersFunder number
Sanoculis Ltd.


    • Glaucoma
    • MIGS
    • MIMS
    • Minimally invasive micro sclerostomy


    Dive into the research topics of 'Minimally invasive micro sclerostomy (MIMS) procedure in the treatment of open-angle glaucoma'. Together they form a unique fingerprint.

    Cite this